HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GNC Making Overnight Image Change In Progress Toward Turnaround

This article was originally published in The Rose Sheet

Executive Summary

The "launch of One New GNC" Dec. 29 at all US company and franchise stores focuses as much on simplifying pricing as on redoing its stores with additional POS terminals to speed checkouts, help customers make decisions based on purchase histories and manage loyalty programs.

You may also be interested in...



'New' GNC Tag Sticks With Turnaround Results Still In 'Early Days'

Acting CEO Robert Moran says' GNC's investment in two loyalty programs, store redesigns in pilot locations, opening an Amazon online storefront and training store clerks to help customers pick products is in "still early days … but it looks like we are headed in the right direction."

GNC Busy Becoming 'New' As Old Business Stifles Earnings

The manufacturer and retailer adds to its turnaround initiative a fee-based customer loyalty piece, "PRO Access," to replace its Gold Card program while also recovering customer traffic with its no-charge "myGNC Rewards" program.

GNC Supply Chain Reform Pays Dividends In DoJ Settlement From DMAA Investigation

DoJ announces a "non-prosecution agreement" that requires GNC to pay $2.25m and to cooperate in dietary supplement market investigations conducted by FDA and other federal agencies, including the current litigation against USPlabs.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108965

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel